Malaysia Dengue Treatment Market By Type (Drug and Vaccine), By Route of Administration (Oral and Parenteral), By End-users (Hospitals, Specialty Clinic, Homecare, and Others), By Region, Competition Forecast & Opportunities 2018-2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationMalaysia Dengue Treatment Market By Type (Drug and Vaccine), By Route of Administration (Oral and Parenteral), By End-users (Hospitals, Specialty Clinic, Homecare, and Others), By Region, Competition Forecast & Opportunities 2018-2028
The Malaysia Dengue Treatment Market is anticipated to grow significantly in the projected period of 2028. The increasing prevalence of dengue in Malaysia is one of the key factors driving the growth of the Dengue Treatment Drugs market. Malaysia is a country in Southeast Asia known for its diverse population, tropical climate, and lush landscapes. However, in recent years, the country has faced a growing threat from dengue fever, a mosquito-borne disease that can cause severe flu-like symptoms and, in some cases, be fatal. As a result, the demand for dengue treatment drugs has been increasing in the country, and it is expected to continue growing in the coming years.
The dengue virus is the source of dengue fever, a mosquito-transmitted tropical disease. Symptoms usually appear three to fourteen days after infection and can include a high fever, headache, nausea, discomfort in the muscles and joints, as well as a typical skin rash and itching. Recovery usually takes two to seven days. In a small percentage of cases, the illness progresses into a more severe form of dengue hemorrhagic fever, which causes bleeding, low blood platelet counts, and blood plasma leakage, or dengue shock syndrome, which causes dangerously low blood pressure. Aedes aegypti is the main species of female mosquitoes in the Aedes genus that transmit dengue. The virus has five different serotypes; infection with one usually confers lifetime immunity against that type, but only temporary immunity to the others. The risk of serious consequences rises when a new type of infection develops later. Several tests, including those that look for antibodies to the virus or its RNA, can be used to confirm the diagnosis.
According to CodeBlue Social Health Analytics, the mortality rate from dengue complications increased by 131.6 percent from 19 deaths in 2021 to 44 deaths in 2022. Additionally, increasing government initiatives are leading to increased awareness about dengue prevalence and prevention among the people of Malaysia. For instance, to lead the fight against dengue, the Malaysian Ministry of Health and the Drugs for Neglected Diseases initiative have joined forces, which is expected to further grow the Malaysia Dengue Treatment Market. The rise in dengue fever cases during the COVID-19 pandemic and the mobility control order (MCO) made it imperative to examine how the general public can prevent the disease, leading to the expansion of the Malaysia Dengue Treatment Market.
Rising Prevalence of Dengue is Booming the Malaysia Dengue Treatment Market
Malaysia is one such country that has been grappling with the burden of dengue for several years. In recent years, the prevalence of dengue in Malaysia has been increasing at an alarming rate, which has led to a surge in demand for dengue treatment drugs. According to the National Library of Medicine, with 397.71 cases per 100,000 people, dengue fever has the highest incidence rate of any infectious disease in Malaysia. Selangor, Wilayah Persekutuan Kuala Lumpur, and Johor are the three Malaysian states with the highest number of reported cases of dengue fever, which is often an urban disease. The situation in Malaysia is worsened by poor clinical management and unfinished vector control operations. The need for the creation of a long-lasting, reasonably priced dengue vaccine that is effective against all infecting serotypes is growing in light of the potential deadly dengue pandemic. Clinical trials are currently testing a number of vaccine candidates, but concerns about serotype interference, insufficient protection, and dose adequacy have been raised. Production of local vaccines should be taken into consideration in conjunction with government efforts to combat dengue, rather than relying solely on outsourcing.
The majority of dengue fever cases can be managed with painkillers at home. The best way to avoid getting dengue is to avoid mosquito bites. Dengue does not have a specific treatment. Treatment of pain symptoms is the main priority. To manage pain, acetaminophen (paracetamol) is frequently used. Ibuprofen and aspirin, two non-steroidal anti-inflammatory medications, are avoided because they raise the chance of bleeding. For those who have experienced dengue at least once and reside in areas where the illness is widespread, there is a vaccine called Dengvaxia. Hospitalization is frequently required for patients with severe dengue, thus augmenting the growth of the Malaysia Dengue Treatment Market. The growing awareness about the importance of Dengue Treatment Drugs and the availability of advanced diagnostic technologies are also driving the Malaysia Dengue Treatment Market. The Malaysian government's efforts to tackle the dengue outbreak are expected to further boost the demand for dengue treatment drugs in the coming years. This presents a significant opportunity for pharmaceutical companies to invest in the development of new and effective dengue treatment drugs, thereby propelling the growth of the Malaysia Dengue Treatment Market.
Rising Technological Advancements Leads to Rising Demand for Malaysia Dengue Treatment Drugs
The Malaysia dengue treatment market is projected to witness significant growth in the coming years, driven by increasing technological advancements, leading to the expansion of the market. Recent developments in point-of-care (POC) and molecular diagnostics, as well as in wireless communication, low-power microelectronics, and wearable sensors, have created new opportunities for the management, clinical monitoring, and real-time surveillance of dengue. According to the International Trade Administration, the Ministry of Health (MOH) has received USD7.7 billion from the government for operating and development costs. With advancements in technology, researchers are continuously developing new and innovative ways to tackle dengue fever. One of the most promising developments is the use of nanotechnology in the treatment of dengue. Nanoparticles have unique properties that make them ideal for drug delivery, and researchers are exploring ways to use them to enhance the efficacy of existing dengue drugs. For example, nanoparticles can be used to increase the bioavailability of drugs, allowing them to reach their target more effectively and efficiently. In addition to nanotechnology, other technological advancements are also contributing to the growth of the Malaysian dengue treatment drugs market. For instance, the use of artificial intelligence (AI) in drug development is gaining traction. AI can be used to analyze vast amounts of data and identify patterns that would be difficult for humans to detect. This can help researchers identify new drug targets and develop more effective drugs for dengue fever. Another technological advancement driving the Malaysian dengue treatment market is the development of new diagnostic tools. Rapid diagnostic tests (RDTs) are becoming increasingly popular for the diagnosis of dengue fever, as they provide quick and accurate results. Moreover, the development of point-of-care testing (POCT) devices has enabled healthcare professionals to diagnose dengue fever in remote or rural areas where laboratory facilities are limited, which is expected to boost the Malaysia Dengue Treatment Market.
Recent Developments
- In October 2023, anexperimental dengue drug created by Johnson & Johnson showed promiseagainst all four types of the virus in mice and prevented infection from twotypes in monkeys. JNJ-1802, which is an early-stage trial of the experimentaltreatment, has already been completed. A randomized Phase II clinical trial forthe drug has been initiated by the company. Johnson & Johnson is usingartificial intelligence (AI) to forecast dengue hotspots, create predictivemodels for dengue incidence, and speed up trial recruitment and site sourcing inaddition to developing JNJ-18.
Mergers and Acquisitions
- In June 2021, in an effort toreimagine global health and increase access to healthcare and medications,Novartis and Hewlett Packard Enterprise (NYSEHPE) announced a partnershipthat aims to accelerate the use of data and digital technologies withinNovartis' initiatives. To assist authorities in proactively deploying responsestrategies targeting at-risk populations, Novartis and Hewlett PackardEnterprise aim to jointly develop publicly available insights. This will helpaddress the growing threat of dengue fever.
Market Segmentation
Malaysia Dengue Treatment Market is segmented into
Company Profiles
Johnson & Johnson, Novartis Corporation (Malaysia) Sdn. Bhd., Otsuka Pharmaceuticals (Malaysia) Sdn. Bhd., GSK Malaysia, Roche Holding Ag Malaysia., Sanofi-Aventis (Malaysia) Sdn. Bhd, Bayer Co. (Malaysia) Sdn Bhd, Merck Sdn Bhd are some of the key players in Malaysia Dengue Treatment Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company shares, competitive landscape, growth factors, and trends |
| Segments covered | Type Route of Administration End-users |
| Country scope | The East Malaysia and The West Malaysia |
| Key companies profiled | Johnson & Johnson, Novartis Corporation (Malaysia) Sdn. Bhd., Otsuka Pharmaceuticals (Malaysia) Sdn. Bhd., GSK Malaysia, Roche Holding Ag Malaysia., Sanofi-Aventis (Malaysia) Sdn. Bhd, Bayer Co. (Malaysia) Sdn Bhd, Merck Sdn Bhd |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Report Scope
In this report, the Malaysia Dengue Treatment Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below
- Malaysia Dengue Treatment Market, By Type
- Drug
- Vaccine
- Malaysia Dengue Treatment Market, By Route of Administration
- Oral
- Parenteral
- Malaysia Dengue Treatment Market, By End-users
- Hospitals
- Specialty Clinic
- Homecare
- Others
- Malaysia Dengue Treatment Market, By Region
- East Malaysia
- West Malaysia
Competitive landscape
Company Profiles
found at Customizations
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are found at for the report
Company Information
- Detailed analysis and profiling of additional market players (up to five).
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy